Injecting trulicity dulaglutide is simple, but proper use is vital for the best results. Always inject into a clean area on the abdomen, thigh, or upper arm, rotating the injection site to avoid ...

European Commission Approves Trulicity® (dulaglutide) Solution for Injection, Lilly's Once-Weekly, Ready-to-Use Type 2 Diabetes Treatment - Trulicity, a glucagon-like peptide-1 (GLP-1) receptor ...

It is available as 0.75mg/0.5mL and 1.5mg/0.5mL strength solutions for subcutaneous (SC) injection in pens or prefilled syringes. For more information call (800) 545-5979 or visit Trulicity.com.

[1/2]Boxes of the drug trulicity, made by Eli Lilly and Company, sit on a counter at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George Frey Purchase Licensing Rights ...

The U.S. Food and Drug Administration today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in ...

The agency on Thursday cleared the drug, Trulicity, as a weekly injection to improve blood sugar control in patients with type 2 diabetes, which affects more than 26 million Americans.

Trulicity is the one of the only approved GLP-receptor agonists that can be injected weekly, rather than daily, a point that the company is marketing to consumers. Patients tend to spend about 6 to 12 ...

Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a once-weekly injection indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.